Eurofins Scientific SE (EPA:ERF) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Shareholders of Eurofins Scientific SE (EPA:ERF) will be pleased this week, given that the stock price is up 12% to €68.76 following its latest interim results. It was a credible result overall, with revenues of €3.6b and statutory earnings per share of €1.83 both in line with analyst estimates, showing that Eurofins Scientific is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Eurofins Scientific after the latest results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the current consensus from Eurofins Scientific's eleven analysts is for revenues of €7.43b in 2025. This would reflect a credible 4.0% increase on its revenue over the past 12 months. Per-share earnings are expected to swell 19% to €2.55. Before this earnings report, the analysts had been forecasting revenues of €7.40b and earnings per share (EPS) of €2.56 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

Check out our latest analysis for Eurofins Scientific

There were no changes to revenue or earnings estimates or the price target of €62.59, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Eurofins Scientific, with the most bullish analyst valuing it at €95.00 and the most bearish at €46.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Eurofins Scientific's growth to accelerate, with the forecast 8.1% annualised growth to the end of 2025 ranking favourably alongside historical growth of 4.9% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 10% annually. It seems obvious that, while the future growth outlook is brighter than the recent past, Eurofins Scientific is expected to grow slower than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Eurofins Scientific's revenue is expected to perform worse than the wider industry. The consensus price target held steady at €62.59, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Eurofins Scientific. Long-term earnings power is much more important than next year's profits. We have forecasts for Eurofins Scientific going out to 2027, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 2 warning signs for Eurofins Scientific that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.